Due to the powerful antitumor potential of IL-18, it has been used in preclinical studies as a tool to increase the proliferation, survival and cytotoxicity of CAR T cells (Chimeric Antigen Receptor T cells) in melanoma [119,120,121,122,123,124] and small cell lung cancer [125]. Here, IL18 is linked to melanoma.